
LINK . SPRINGER . COM {
}
Title:
Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway | Molecular Cancer
Description:
Background We previously reported the identification of ONC201/TIC10, a novel small molecule inducer of the human TRAIL gene that improves efficacy-limiting properties of recombinant TRAIL and is in clinical trials in advanced cancers based on its promising safety and antitumor efficacy in several preclinical models. Methods We performed a high throughput luciferase reporter screen using the NCI Diversity Set II to identify TRAIL-inducing compounds. Results Small molecule-mediated induction of TRAIL reporter activity was relatively modest and the majority of the hit compounds induced low levels of TRAIL upregulation. Among the candidate TRAIL-inducing compounds, TIC9 and ONC201/TIC10 induced sustained TRAIL upregulation and apoptosis in tumor cells in vitro and in vivo. However, ONC201/TIC10 potentiated tumor cell death while sparing normal cells, unlike TIC9, and lacked genotoxicity in normal fibroblasts. Investigating the effects of TRAIL-inducing compounds on cell signaling pathways revealed that TIC9 and ONC201/TIC10, which are the most potent inducers of cell death, exclusively activate Foxo3a through inactivation of Akt/ERK to upregulate TRAIL and its pro-apoptotic death receptor DR5. Conclusion These studies reveal the selective activity of ONC201/TIC10 that led to its selection as a lead compound for this novel class of antitumor agents and suggest that ONC201/TIC10 is a unique inducer of the TRAIL pathway through its concomitant regulation of the TRAIL ligand and its death receptor DR5.
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {π}
- Science
- Education
- Telecommunications
Content Management System {π}
What CMS is link.springer.com built with?
Custom-built
No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.
Traffic Estimate {π}
What is the average monthly size of link.springer.com audience?
π Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {πΈ}
We don't see any clear sign of profit-making.
Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.
Keywords {π}
trail, cells, onctic, tic, article, cell, tumor, gene, pubmed, cancer, google, scholar, death, trailinducing, compounds, human, figure, activity, cas, reporter, hct, small, apoptosis, normal, induction, levels, foxoa, induce, analysis, molecule, receptor, ligand, vivo, studies, study, screen, compound, molecules, promoter, dose, treated, content, anticancer, allen, dicker, eldeiry, clinical, antitumor, selection, mechanism,
Topics {βοΈ}
tumour-necrosis factor superfamily trail-independent pro-apoptotic effects akt/foxo3a/trail-dependent manner onc201/tic10-induced cell death identify trail-inducing compounds trail pathway-inducing compound dna-damaging chemotherapy doxorubicin lead trail-inducing compound top trail-inducing compounds extracellular signal-regulated kinases trail-independent apoptotic activity candidate trail-inducing compounds leukemic stem/progenitor cells bcr-abl mediate suppression hrp-conjugated secondary antibody unique anti-cancer agent full size image tumor cell-specific targeting selected trail-inducing compounds improve trail-inducing compounds validation trail-inducing compounds tic-treated xenograft tumors related subjects antibody targeting trail-r1 onc201/tic10 potently inhibited trail-mediated cell death approved anti-cancer compounds onc201/tic10-induced trail onc201/tic10-induced dr5 anti-gamma h2ax antibody open access license monocyte-mediated tumoricidal activity restore anti-tumor immunity potent anti-cancer activity onc201/tic10 induce trail improves efficacy-limiting properties receptor-selective variant dr5 onc201/tic10 upregulate trail classic er stress-inducer refractory colorectal cancer cell-based reporter system bio-rad protein assay trail-inducing compounds potent anti-tumor effects exclusively activate foxo3a article download pdf inducing cell death inducing high levels dr5 gene promoter molecule induced apoptosis
Questions {β}
- A Better TRAIL Variant for Tumor Cell-Specific Targeting?
Schema {πΊοΈ}
WebPage:
mainEntity:
headline:Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
description:We previously reported the identification of ONC201/TIC10, a novel small molecule inducer of the human TRAIL gene that improves efficacy-limiting properties of recombinant TRAIL and is in clinical trials in advanced cancers based on its promising safety and antitumor efficacy in several preclinical models. We performed a high throughput luciferase reporter screen using the NCI Diversity Set II to identify TRAIL-inducing compounds. Small molecule-mediated induction of TRAIL reporter activity was relatively modest and the majority of the hit compounds induced low levels of TRAIL upregulation. Among the candidate TRAIL-inducing compounds, TIC9 and ONC201/TIC10 induced sustained TRAIL upregulation and apoptosis in tumor cells in vitro and in vivo. However, ONC201/TIC10 potentiated tumor cell death while sparing normal cells, unlike TIC9, and lacked genotoxicity in normal fibroblasts. Investigating the effects of TRAIL-inducing compounds on cell signaling pathways revealed that TIC9 and ONC201/TIC10, which are the most potent inducers of cell death, exclusively activate Foxo3a through inactivation of Akt/ERK to upregulate TRAIL and its pro-apoptotic death receptor DR5. These studies reveal the selective activity of ONC201/TIC10 that led to its selection as a lead compound for this novel class of antitumor agents and suggest that ONC201/TIC10 is a unique inducer of the TRAIL pathway through its concomitant regulation of the TRAIL ligand and its death receptor DR5.
datePublished:2015-05-01T00:00:00Z
dateModified:2024-10-18T00:00:00Z
pageStart:1
pageEnd:10
license:https://creativecommons.org/publicdomain/zero/1.0/
sameAs:https://doi.org/10.1186/s12943-015-0346-9
keywords:
ONC201
TIC10
TRAIL
TRAIL-inducing compound
TNF-related apoptosis-inducing ligand
DR5
Foxo3a
Gene regulation
Cancer Research
Oncology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig1_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig2_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig3_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig4_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig5_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig6_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig7_HTML.gif
isPartOf:
name:Molecular Cancer
issn:
1476-4598
volumeNumber:14
type:
Periodical
PublicationVolume
publisher:
name:BioMed Central
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Joshua E Allen
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
name:Current affiliation: Oncoceutics, Inc.
address:
name:Current affiliation: Oncoceutics, Inc., Hummelstown, USA
type:PostalAddress
type:Organization
type:Person
name:Gabriel Krigsfeld
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:Luv Patel
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:Patrick A Mayes
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:David T Dicker
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
name:Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center
address:
name:Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:Gen Sheng Wu
affiliation:
name:Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Wayne State University School of Medicine
address:
name:Department of Pathology, Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA
type:PostalAddress
type:Organization
type:Person
name:Wafik S El-Deiry
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
name:Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center
address:
name:Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:1
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
description:We previously reported the identification of ONC201/TIC10, a novel small molecule inducer of the human TRAIL gene that improves efficacy-limiting properties of recombinant TRAIL and is in clinical trials in advanced cancers based on its promising safety and antitumor efficacy in several preclinical models. We performed a high throughput luciferase reporter screen using the NCI Diversity Set II to identify TRAIL-inducing compounds. Small molecule-mediated induction of TRAIL reporter activity was relatively modest and the majority of the hit compounds induced low levels of TRAIL upregulation. Among the candidate TRAIL-inducing compounds, TIC9 and ONC201/TIC10 induced sustained TRAIL upregulation and apoptosis in tumor cells in vitro and in vivo. However, ONC201/TIC10 potentiated tumor cell death while sparing normal cells, unlike TIC9, and lacked genotoxicity in normal fibroblasts. Investigating the effects of TRAIL-inducing compounds on cell signaling pathways revealed that TIC9 and ONC201/TIC10, which are the most potent inducers of cell death, exclusively activate Foxo3a through inactivation of Akt/ERK to upregulate TRAIL and its pro-apoptotic death receptor DR5. These studies reveal the selective activity of ONC201/TIC10 that led to its selection as a lead compound for this novel class of antitumor agents and suggest that ONC201/TIC10 is a unique inducer of the TRAIL pathway through its concomitant regulation of the TRAIL ligand and its death receptor DR5.
datePublished:2015-05-01T00:00:00Z
dateModified:2024-10-18T00:00:00Z
pageStart:1
pageEnd:10
license:https://creativecommons.org/publicdomain/zero/1.0/
sameAs:https://doi.org/10.1186/s12943-015-0346-9
keywords:
ONC201
TIC10
TRAIL
TRAIL-inducing compound
TNF-related apoptosis-inducing ligand
DR5
Foxo3a
Gene regulation
Cancer Research
Oncology
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig1_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig2_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig3_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig4_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig5_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig6_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-015-0346-9/MediaObjects/12943_2015_346_Fig7_HTML.gif
isPartOf:
name:Molecular Cancer
issn:
1476-4598
volumeNumber:14
type:
Periodical
PublicationVolume
publisher:
name:BioMed Central
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Joshua E Allen
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
name:Current affiliation: Oncoceutics, Inc.
address:
name:Current affiliation: Oncoceutics, Inc., Hummelstown, USA
type:PostalAddress
type:Organization
type:Person
name:Gabriel Krigsfeld
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:Luv Patel
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:Patrick A Mayes
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:David T Dicker
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
name:Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center
address:
name:Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
type:Person
name:Gen Sheng Wu
affiliation:
name:Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Wayne State University School of Medicine
address:
name:Department of Pathology, Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA
type:PostalAddress
type:Organization
type:Person
name:Wafik S El-Deiry
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
name:Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center
address:
name:Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:1
["Periodical","PublicationVolume"]:
name:Molecular Cancer
issn:
1476-4598
volumeNumber:14
Organization:
name:BioMed Central
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
name:Current affiliation: Oncoceutics, Inc.
address:
name:Current affiliation: Oncoceutics, Inc., Hummelstown, USA
type:PostalAddress
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
name:Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center
address:
name:Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
name:Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Wayne State University School of Medicine
address:
name:Department of Pathology, Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA
type:PostalAddress
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
name:Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center
address:
name:Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Joshua E Allen
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
name:Current affiliation: Oncoceutics, Inc.
address:
name:Current affiliation: Oncoceutics, Inc., Hummelstown, USA
type:PostalAddress
type:Organization
name:Gabriel Krigsfeld
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
name:Luv Patel
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
name:Patrick A Mayes
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
name:David T Dicker
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
name:Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center
address:
name:Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
name:Gen Sheng Wu
affiliation:
name:Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Wayne State University School of Medicine
address:
name:Department of Pathology, Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA
type:PostalAddress
type:Organization
name:Wafik S El-Deiry
affiliation:
name:University of Pennsylvania School of Medicine
address:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
type:PostalAddress
type:Organization
name:Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center
address:
name:Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, USA
type:PostalAddress
type:Organization
email:[email protected]
PostalAddress:
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
name:Current affiliation: Oncoceutics, Inc., Hummelstown, USA
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
name:Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, USA
name:Department of Pathology, Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA
name:Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, USA
name:Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, USA
External Links {π}(130)
- How much revenue does https://www.springernature.com/gp/authors produce monthly?
- Check the income stats for https://link.springernature.com/home/
- How much money does https://order.springer.com/public/cart generate?
- How much does https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research net monthly?
- How much does https://molecular-cancer.biomedcentral.com/about bring in each month?
- What are the total earnings of https://submission.nature.com/new-submission/12943/3?
- What's https://doi.org/10.1186/s12943-024-02158-w's gross income?
- What's the total monthly financial gain of https://doi.org/10.1038%2Fnrc821?
- What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12189384's gross income?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Targeting%20death%20and%20decoy%20receptors%20of%20the%20tumour-necrosis%20factor%20superfamily&journal=Nat%20Rev%20Cancer&doi=10.1038%2Fnrc821&volume=2&pages=420-30&publication_year=2002&author=Ashkenazi%2CA?
- How much does https://doi.org/10.1016%2F1074-7613%2895%2990057-8 pull in monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8777713 pull in?
- How much money does http://scholar.google.com/scholar_lookup?&title=Identification%20and%20characterization%20of%20a%20new%20member%20of%20the%20TNF%20family%20that%20induces%20apoptosis&journal=Immunity&doi=10.1016%2F1074-7613%2895%2990057-8&volume=3&pages=673-82&publication_year=1995&author=Wiley%2CSR&author=Schooley%2CK&author=Smolak%2CPJ&author=Din%2CWS&author=Huang%2CCP&author=Nicholl%2CJK make?
- How much income does https://doi.org/10.1084%2Fjem.190.8.1155 have?
- How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2195665 pull in?
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10523613 generate?
- How much money does http://scholar.google.com/scholar_lookup?&title=Human%20dendritic%20cells%20mediate%20cellular%20apoptosis%20via%20tumor%20necrosis%20factor-related%20apoptosis-inducing%20ligand%20%28Trail%29&journal=J%20Exp%20Med&doi=10.1084%2Fjem.190.8.1155&volume=190&pages=1155-64&publication_year=1999&author=Fanger%2CNA&author=Maliszewski%2CCR&author=Schooley%2CK&author=Griffith%2CTS generate?
- What's the financial outcome of https://doi.org/10.1084%2Fjem.189.8.1343?
- How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193036 have monthly?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10209050 earn?
- How much profit is http://scholar.google.com/scholar_lookup?&title=Monocyte-mediated%20tumoricidal%20activity%20via%20the%20tumor%20necrosis%20factor-related%20cytokine%2C%20TRAIL&journal=J%20Exp%20Med&doi=10.1084%2Fjem.189.8.1343&volume=189&pages=1343-54&publication_year=1999&author=Griffith%2CTS&author=Wiley%2CSR&author=Kubin%2CMZ&author=Sedger%2CLM&author=Maliszewski%2CCR&author=Fange%2CNA making per month?
- What's the income of https://doi.org/10.4049%2Fjimmunol.173.2.892?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15240676 net monthly?
- What are the total earnings of http://scholar.google.com/scholar_lookup?&title=Human%20B%20cells%20express%20functional%20TRAIL%2FApo-2%20ligand%20after%20CpG-containing%20oligodeoxynucleotide%20stimulation&journal=J%20Immunol&doi=10.4049%2Fjimmunol.173.2.892&volume=173&pages=892-9&publication_year=2004&author=Kemp%2CTJ&author=Moore%2CJM&author=Griffith%2CTS?
- What's the income of https://doi.org/10.1084%2Fjem.188.12.2375?
- See how much http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212426 makes per month
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9858524 generate monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=Natural%20Killer%20%28NK%29%20cell-mediated%20cytotoxicity%3A%20differential%20use%20of%20TRAIL%20and%20fas%20ligand%20by%20immature%20and%20mature%20primary%20human%20NK%20cells&journal=J%20Exp%20Med&doi=10.1084%2Fjem.188.12.2375&volume=188&pages=2375-80&publication_year=1998&author=Zamai%2CL&author=Ahmad%2CM&author=Bennett%2CIM&author=Azzoni%2CL&author=Alnemri%2CES&author=Perussia%2CB pull in?
- https://doi.org/10.1016%2Fj.lungcan.2007.12.011 income
- Financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18255187
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Phase%202%20study%20of%20mapatumumab%2C%20a%20fully%20human%20agonistic%20monoclonal%20antibody%20which%20targets%20and%20activates%20the%20TRAIL%20receptor-1%2C%20in%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer&journal=Lung%20Cancer&doi=10.1016%2Fj.lungcan.2007.12.011&volume=61&pages=82-90&publication_year=2008&author=Greco%2CFA&author=Bonomi%2CP&author=Crawford%2CJ&author=Kelly%2CK&author=Oh%2CY&author=Halpern%2CW produce monthly?
- https://doi.org/10.1158%2F1078-0432.CCR-09-1267's revenue stream
- What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20145186's gross income?
- http://scholar.google.com/scholar_lookup?&title=A%20phase%20I%20safety%20and%20pharmacokinetic%20study%20of%20the%20death%20receptor%205%20agonistic%20antibody%20PRO95780%20in%20patients%20with%20advanced%20malignancies&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-09-1267&volume=16&pages=1256-63&publication_year=2010&author=Camidge%2CDR&author=Herbst%2CRS&author=Gordon%2CMS&author=Eckhardt%2CSG&author=Kurzrock%2CR&author=Durbin%2CB's total income per month
- What's the total monthly financial gain of https://doi.org/10.1038%2Fsj.bjc.6605507?
- What's the financial gain of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822942?
- What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20068564?
- What are the total earnings of http://scholar.google.com/scholar_lookup?&title=Phase%20II%20trial%20of%20mapatumumab%2C%20a%20fully%20human%20agonistic%20monoclonal%20antibody%20that%20targets%20and%20activates%20the%20tumour%20necrosis%20factor%20apoptosis-inducing%20ligand%20receptor-1%20%28TRAIL-R1%29%2C%20in%20patients%20with%20refractory%20colorectal%20cancer&journal=Br%20J%20Cancer&doi=10.1038%2Fsj.bjc.6605507&volume=102&pages=506-12&publication_year=2010&author=Trarbach%2CT&author=Moehler%2CM&author=Heinemann%2CV&author=K%C3%B6hne%2CCH&author=Przyborek%2CM&author=Schulz%2CC?
- Earnings of https://doi.org/10.1158%2F1078-0432.CCR-09-0996
- Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19690193
- http://scholar.google.com/scholar_lookup?&title=Mapatumumab%2C%20a%20fully%20human%20agonistic%20monoclonal%20antibody%20that%20targets%20TRAIL-R1%2C%20in%20combination%20with%20gemcitabine%20and%20cisplatin%3A%20a%20phase%20I%20study&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-09-0996&volume=15&pages=5584-90&publication_year=2009&author=Mom%2CCH&author=Verweij%2CJ&author=Oldenhuis%2CCN&author=Gietema%2CJA&author=Fox%2CNL&author=Miceli%2CR's total income per month
- What's the monthly money flow for https://doi.org/10.1200%2FJCO.2008.21.7422?
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19652058 generate?
- Earnings of http://scholar.google.com/scholar_lookup?&title=Mapatumumab%2C%20an%20antibody%20targeting%20TRAIL-R1%2C%20in%20combination%20with%20paclitaxel%20and%20carboplatin%20in%20patients%20with%20advanced%20solid%20malignancies%3A%20results%20of%20a%20phase%20I%20and%20pharmacokinetic%20study&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2008.21.7422&volume=27&pages=4413-21&publication_year=2009&author=Leong%2CS&author=Cohen%2CRB&author=Gustafson%2CDL&author=Langer%2CCJ&author=Camidge%2CDR&author=Padavic%2CK
- What are the total earnings of https://doi.org/10.1158%2F1078-0432.CCR-07-0950?
- What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17947486?
- Get to know http://scholar.google.com/scholar_lookup?&title=Phase%201%20and%20pharmacokinetic%20study%20of%20lexatumumab%20in%20patients%20with%20advanced%20cancers&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-07-0950&volume=13&pages=6187-94&publication_year=2007&author=Plummer%2CR&author=Attard%2CG&author=Pacey%2CS&author=Li%2CL&author=Razak%2CA&author=Perrett%2CR's earnings
- What is the monthly revenue of https://doi.org/10.1200%2FJCO.2006.08.8898?
- What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17416859?
- http://scholar.google.com/scholar_lookup?&title=Phase%20I%20pharmacokinetic%20and%20biologic%20correlative%20study%20of%20Mapatumumab%2C%20a%20fully%20human%20monoclonal%20antibody%20with%20agonist%20activity%20to%20tumor%20necrosis%20factor%20related%20apoptosis-inducing%20ligand%20receptor-1&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2006.08.8898&volume=25&pages=1390-6&publication_year=2007&author=Tolcher%2CAW&author=Mita%2CM&author=Meropol%2CNJ&author=Mehren%2CM&author=Patnaik%2CA&author=Padavic%2CK's financial summary
- Explore the financials of https://doi.org/10.1517%2F14728222.2010.519701
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20819019 bring in each month?
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=TRAIL%20receptor%20signaling%20and%20therapeutics&journal=Expert%20Opin%20Ther%20Targets&doi=10.1517%2F14728222.2010.519701&volume=14&pages=1091-108&publication_year=2010&author=Abdulghani%2CJ&author=El-Deiry%2CWS?
- Find out how much https://doi.org/10.1158%2F1535-7163.MCT-10-0621 earns monthly
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20924127's total income per month
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=A%20Better%20TRAIL%20Variant%20for%20Tumor%20Cell-Specific%20Targeting%3F%20-%20Letter&journal=Mol%20Cancer%20Ther&doi=10.1158%2F1535-7163.MCT-10-0621&volume=9&publication_year=2010&author=Bremer%2CE&author=Helfrich%2CW?
- How much does https://doi.org/10.1038%2F5517 earn?
- What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9930862?
- How profitable is http://scholar.google.com/scholar_lookup?&title=Tumoricidal%20activity%20of%20tumor%20necrosis%20factor-related%20apoptosis-inducing%20ligand%20in%20vivo&journal=Nat%20Med&doi=10.1038%2F5517&volume=5&pages=157-63&publication_year=1999&author=Walczak%2CH&author=Miller%2CRE&author=Ariail%2CK&author=Gliniak%2CB&author=Griffith%2CTS&author=Kubin%2CM?
- Monthly income for https://doi.org/10.1158%2F1078-0432.CCR-05-2635
- Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16638878
- Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Preclinical%20differentiation%20between%20apparently%20safe%20and%20potentially%20hepatotoxic%20applications%20of%20TRAIL%20either%20alone%20or%20in%20combination%20with%20chemotherapeutic%20drugs&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-05-2635&volume=12&pages=2640-6&publication_year=2006&author=Ganten%2CTM&author=Koschny%2CR&author=Sykora%2CJ&author=Schulze-Bergkamen%2CH&author=B%C3%BCchler%2CP&author=Haas%2CTL
- Learn how profitable https://doi.org/10.1158%2F1535-7163.MCT-12-0366 is on a monthly basis
- How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22802267 bring in?
- How profitable is http://scholar.google.com/scholar_lookup?&title=Targeting%20TRAIL%20death%20receptor%204%20with%20trivalent%20DR4%20Atrimer%20complexes&journal=Mol%20Cancer%20Ther&doi=10.1158%2F1535-7163.MCT-12-0366&volume=11&pages=2087-95&publication_year=2012&author=Allen%2CJE&author=Ferrini%2CR&author=Dicker%2CDT&author=Batzer%2CG&author=Chen%2CE&author=Oltean%2CDI?
- How much money does https://doi.org/10.1002%2Fstem.136 make?
- How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19544410 make?
- How much does http://scholar.google.com/scholar_lookup?&title=Human%20bone%20marrow-derived%20mesenchymal%20stromal%20cells%20expressing%20S-TRAIL%20as%20a%20cellular%20delivery%20vehicle%20for%20human%20glioma%20therapy&journal=Stem%20Cells&doi=10.1002%2Fstem.136&volume=27&pages=2320-30&publication_year=2009&author=Menon%2CLG&author=Kelly%2CK&author=Yang%2CHW&author=Kim%2CSK&author=Black%2CPM&author=Carroll%2CRS bring in each month?
- What is the monthly revenue of https://doi.org/10.1038%2Fnchembio.1153?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23292651 pull in monthly?
- Earnings of http://scholar.google.com/scholar_lookup?&title=Small-molecule%20activation%20of%20the%20TRAIL%20receptor%20DR5%20in%20human%20cancer%20cells&journal=Nat%20Chem%20Biol&doi=10.1038%2Fnchembio.1153&volume=9&pages=84-9&publication_year=2013&author=Wang%2CG&author=Wang%2CX&author=Yu%2CH&author=Wei%2CS&author=Williams%2CN&author=Holmes%2CDL
- How much revenue does https://doi.org/10.4161%2Fcbt.21354 generate?
- Monthly income for http://scholar.google.com/scholar_lookup?&title=Regulation%20of%20the%20human%20TRAIL%20gene&journal=Canc%20Biol%20Ther&doi=10.4161%2Fcbt.21354&volume=13&pages=1143-51&publication_year=2012&author=Allen%2CJE&author=El-Deiry%2CWS
- What's the monthly money flow for https://doi.org/10.4161%2Fcbt.7.12.7460?
- How much does http://scholar.google.com/scholar_lookup?&title=TNFSF10%20%28TRAIL%29%2C%20a%20p53%20target%20gene%20that%20mediates%20p53-dependent%20cell%20death&journal=Canc%20Biol%20Ther&doi=10.4161%2Fcbt.7.12.7460&volume=7&pages=2034-8&publication_year=2008&author=Kuribayashi%2CK&author=Krigsfeld%2CG&author=Wang%2CW&author=Xu%2CJ&author=Mayes%2CPA&author=Dicker%2CDT pull in?
- How much does https://doi.org/10.1073%2Fpnas.0731871100 rake in every month?
- What's the monthly income of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC164479?
- What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12750477?
- How much income is http://scholar.google.com/scholar_lookup?&title=Cytokines%20and%20BCR-ABL%20mediate%20suppression%20of%20TRAIL-induced%20apoptosis%20through%20inhibition%20of%20forkhead%20FOXO3a%20transcription%20factor&journal=Proc%20Natl%20Acad%20Sci&doi=10.1073%2Fpnas.0731871100&volume=100&pages=6523-8&publication_year=2003&author=Ghaffari%2CS&author=Jagani%2CZ&author=Kitidis%2CC&author=Lodish%2CHF&author=Khosravi-Far%2CR earning monthly?
- How much does https://doi.org/10.1172%2FJCI6863 bring in each month?
- Earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC408422
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10430607 generate?
- Monthly income for http://scholar.google.com/scholar_lookup?&title=Disruption%20of%20p53%20in%20human%20cancer%20cells%20alters%20the%20responses%20to%20therapeutic%20agents&journal=J%20Clin%20Investig&doi=10.1172%2FJCI6863&volume=104&pages=263-9&publication_year=1999&author=Bunz%2CF&author=Hwang%2CPM&author=Torrance%2CC&author=Waldman%2CT&author=Zhang%2CY&author=Dillehay%2CL
- Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11486001
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Identification%20of%20Inhibitors%20of%20TRAIL-induced%20Death%20%28ITIDs%29%20in%20the%20TRAIL-sensitive%20colon%20carcinoma%20cell%20line%20SW480%20using%20a%20genetic%20approach&journal=J%20Biol%20Chem&volume=276&pages=37879-86&publication_year=2001&author=Burns%2CTF&author=El-Deiry%2CWS bring in?
- How much does https://doi.org/10.1126%2Fscitranslmed.3004828 net monthly?
- See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23390247 makes per month
- http://scholar.google.com/scholar_lookup?&title=Dual%20inactivation%20of%20Akt%20and%20ERK%20by%20TIC10%20signals%20Foxo3a%20nuclear%20translocation%2C%20TRAIL%20gene%20induction%20and%20potent%20anti-tumor%20effects&journal=Sci%20Transl%20Med&doi=10.1126%2Fscitranslmed.3004828&volume=5&publication_year=2013&author=Allen%2CJE&author=Krigsfeld%2CG&author=Mayes%2CPA&author=Patel%2CL&author=Dicker%2CDT&author=Patel%2CAS's financial summary
- How profitable is https://doi.org/10.1053%2Fj.gastro.2011.06.026?
- Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21699898
- How profitable is http://scholar.google.com/scholar_lookup?&title=Oxaliplatin%20uses%20JNK%20to%20restore%20TRAIL%20sensitivity%20in%20cancer%20cells%20through%20Bcl-xL%20inactivation&journal=Gastroenterology&doi=10.1053%2Fj.gastro.2011.06.026&volume=141&pages=430-4&publication_year=2011&author=Allen%2CJE&author=El-Deiry%2CWS?
- What's the income of https://doi.org/10.1038%2Fng1097-141?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=KILLER%2FDR5%20is%20a%20DNA%20damage-inducible%20p53-regulated%20death%20receptor%20gene&journal=Nat%20Genet&doi=10.1038%2Fng1097-141&volume=17&pages=141-3&publication_year=2014&author=Wu%2CGS&author=Burns%2CTF&author=McDonald%2CER&author=Jiang%2CW&author=Meng%2CR&author=Krantz%2CID generate?
- Check the income stats for http://scholar.google.com/scholar_lookup?&title=Is%20a%20potent%20inducer%20of%20apoptosis%20in%20human%20cancer%20cells%20independently%20of%20p53&journal=Exp%20Cell%20Res&volume=2&pages=190-6&publication_year=2014&author=Shao%2CR-G&author=Shimizu%2CT&author=Pommier%2CY&author=Brefeldin%2CA
- How much revenue does http://scholar.google.com/scholar_lookup?&title=ONC201%20induces%20p53-independent%20apoptosis%20and%20cell%20cycle%20arrest%20in%20hematological%20malignancies%20and%20leukemic%20stem%2Fprogenitor%20cells%20by%20inducing%20ER%20stress%20and%20mTOR%20inhibition&journal=Blood&volume=124&publication_year=2014&author=Ishizawa%2CJ&author=Kojima%2CK&author=Chachad%2CD&author=Ruvolo%2CPP&author=Ruvolo%2CVR&author=Jacamo%2CR generate?
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350349's total income per month
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25587031 gross monthly?
- What's the revenue for http://scholar.google.com/scholar_lookup?&title=The%20angular%20structure%20of%20ONC201%2C%20a%20TRAIL%20pathway-inducing%20compound%2C%20determines%20its%20potent%20anti-cancer%20activity&journal=Oncotarget&volume=5&pages=12728-37&publication_year=2014&author=Wagner%2CJ&author=Kline%2CCL&author=Pottorf%2CRS&author=Nallaganchu%2CBR&author=Olson%2CGL&author=Dicker%2CDT?
- What's the financial outcome of https://citation-needed.springer.com/v2/references/10.1186/s12943-015-0346-9?format=refman&flavour=references?
- Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Joshua%20E%20Allen
- Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Joshua%20E%20Allen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Gabriel%20Krigsfeld
- Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Gabriel%20Krigsfeld%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Luv%20Patel gross monthly?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Luv%20Patel%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- How much profit is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Patrick%20A%20Mayes making per month?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Patrick%20A%20Mayes%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
- How profitable is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=David%20T%20Dicker?
- What's the financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22David%20T%20Dicker%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- Explore the financials of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Gen%20Sheng%20Wu
- What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Gen%20Sheng%20Wu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Wafik%20S%20El-Deiry bring in?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Wafik%20S%20El-Deiry%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's financial summary
- How much does https://crossmark.crossref.org/dialog/?doi=10.1186/s12943-015-0346-9 bring in each month?
- Get to know https://citation-needed.springer.com/v2/references/10.1186/s12943-015-0346-9?format=refman&flavour=citation's earnings
- How much income is https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral earning monthly?
- What's the financial outcome of https://www.springernature.com/gp/products?
- See how much https://www.springernature.com/gp/librarians makes per month
- How much does https://www.springernature.com/gp/societies pull in monthly?
- How much profit is https://www.springernature.com/gp/partners making per month?
- How much profit does https://www.springer.com/ make?
- How much revenue does https://www.nature.com/ bring in?
- How much profit does https://www.biomedcentral.com/ make?
- Monthly income for https://www.palgrave.com/
- How profitable is https://www.apress.com/?
- How much income is https://www.springernature.com/gp/legal/ccpa earning monthly?
- How much does https://www.springernature.com/gp/info/accessibility rake in every month?
- How much profit does https://support.springernature.com/en/support/home make?
- How much does https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations gross monthly?
- How much does https://www.springernature.com/ bring in each month?
Analytics and Tracking {π}
- Google Tag Manager
Libraries {π}
- Clipboard.js
- Prism.js
CDN Services {π¦}
- Crossref